Guan Y S, Liu Y, Zhou X P, Li X, He Q, Sun L
Department of Radiology, West China Hospital, Sichuan University, 37 Guoxuexiang, Chengdu 610041, Sichuan Province, China.
Gut. 2005 Sep;54(9):1318-9. doi: 10.1136/gut.2005.069237. Epub 2005 May 5.
Transcatheter arterial chemoembolisation (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC). However, this method is often unsuccessful. The p53 gene, which is present as a mutant form in many human tumours, is known to have broad spectrum antitumour effects when expressed normally. In this study, we report a 23 year old patient with recurrent HCC who was treated with the p53 gene (Gendicine) combining TACE, which resulted in a good clinical prognosis.
经动脉化疗栓塞术（TACE）已成为不可切除肝细胞癌（HCC）的标准治疗方法。然而，这种方法常常不成功。p53基因在许多人类肿瘤中以突变形式存在，已知其正常表达时具有广谱抗肿瘤作用。在本研究中，我们报告了一名23岁复发性HCC患者，其接受了p53基因（重组人p53腺病毒注射液）联合TACE治疗，临床预后良好。
